PharmAthene, Inc. [PIP] has completed its acquisition of the biodefense vaccines business unit from the United Kingdom's Avecia Biologics in a deal that bolsters its portfolio of anthrax vaccine capabilities and gives it a potential product for plague vaccine. Terms of the deal include a $10 million cash payment and additional $7 million to be paid within 18 months of the closing. Avecia will also be able to receive payments up to $23 million contingent upon the achievement of certain…
Recommended
True Anomaly and Northrop Grumman Aiming to Build GHOST-R Prototypes to Reduce RG-XX Costs
Trending
Congress Updates
CBO Estimates Loss of One-Half to Two-Thirds of U.S. Missile Interceptors Since June Last Year
A new Congressional Budget Office report estimates the cost of the Iran war through Aug. 1 as $38 billion and says that the U.S. has likely depleted between one-half and […]
Fischer Says Golden Dome Boosters Need To Increase Capitol Hill Support With Information, Warns Against Counting On Reconciliation
NATIONAL HARBOR, Md. – A Senate Armed Services panel chair today said boosters of the Golden Dome program still have work to do to increase support on Capitol Hill while […]
HII Executive Outlines Its Shipbuilding Acceleration Strategy
An HII [HII] shipbuilding executive last week told lawmakers how the company plans to improve and accelerate shipbuilding throughout via workforce improvements, adding new shipbuilding infrastructure and reinforcing distributed shipbuilding […]
House Sends Dec. 11 CR With Ship Construction Funds To Trump’s Desk For Final Signature
The House on Tuesday passed a stopgap funding bill to keep the government open through Dec. 11, sending the temporary funding measure that also includes funds to support ongoing shipbuilding […]